SGEN - Seattle Genetics, Inc.
| Previous Close | 77.50 |
| Open | 77.77 |
| Bid | 71.50 x 1400 |
| Ask | 80.00 x 800 |
| Day's Range | 77.51 - 79.16 |
| 52 Week Range | 47.75 - 79.16 |
| Volume | 948,970 |
| Avg. Volume | 732,000 |
| Market Cap | 12.544B |
| Beta | 1.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings Date | Oct 24, 2018 - Oct 29, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 77.00 |
- Market Realist•8 minutes ago
Estimates and Recommendations for Shire on September 19
Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.
Markit•yesterdaySee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Simply Wall St.•2 days ago
Why Seattle Genetics Inc (NASDAQ:SGEN) Is A Financially Healthy Company
Investors looking for stocks with high market liquidity and zero debt on the balance sheet should consider Seattle Genetics Inc (NASDAQ:SGEN). With a market valuation of US$12.09b, SGEN is aRead More...
- Market Realist•15 days ago
Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.
Market Realist•16 days agoHow’s Alkermes Positioned Financially in September?
In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017, which reflects ~39% growth year-over-year. In the second quarter, Alkermes generated revenues of $128.2 million as manufacturing and royalty revenues. Alkermes reported revenues of $109.8 from product sales in the second quarter—compared to $88.7 million in the second quarter of 2017.
- Business Wire•17 days ago
Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference
Seattle Genetics, Inc. announced today that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.m. EDT.
Markit•27 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Zacks•last month
Bayer Plunges as Monsanto Fined $289M in Roundup Lawsuit
Shares of Bayer (BAYRY) crash as its newly acquired company Monsanto was fined $289 million over allegations that its weedkiller caused cancer.
Motley Fool•last month(UMRX) Q2 2018 Earnings Conference Call Transcript
UMRX earnings call for the period ending June 30, 2018.
- Thomson Reuters StreetEvents•last month
Edited Transcript of SGEN earnings conference call or presentation 26-Jul-18 8:30pm GMT
Q2 2018 Seattle Genetics Inc Earnings Call
Markit•last monthSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Zacks•last month
Spectrum (SPPI) Earnings and Sales Miss Estimates in Q2
Spectrum (SPPI) reports wider-than-expected loss in the second quarter and misses on revenues. Rolontis successful in second phase III study.
- Zacks•last month
Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates
Celldex (CLDX) reports narrower-than-expected loss in Q2. Revenues fell due to reduced contract revenues.
- Zacks•last month
Nektar (NKTR) Q2 Earnings In Line, Product Sales Down Y/Y
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
- Zacks•last month
Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales
Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.
- Zacks•last month
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.
- Zacks•last month
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2
The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.
- Zacks•last month
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.
- Zacks•last month
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.
- Zacks•last month
Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected
Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.
Market Realist•2 months agoHow Neurocrine Biosciences Performed in the Second Quarter
Neurocrine Biosciences (NBIX) generated revenues of $96.9 million in the second quarter of 2018 compared to $6.3 billion in the second quarter of 2017. In the second quarter of 2018, Neurocrine Biosciences witnessed ~36% growth sequentially. In the first half of 2018, Neurocrine Biosciences generated revenues of $168.0 million.
- Market Realist•2 months ago
What Do Analysts Expect from Ionis’s Q2 2018 Earnings?
Ionis Pharmaceuticals (IONS) is one of the leading RNA-targeted therapeutics companies. The company aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes approved products in collaboration with other pharmaceutical companies. Ionis is set to release its Q2 2018 earnings on August 7. Wall Street analysts estimate a net loss of $0.09 per share on revenues of $135.5 million in the second quarter of 2018.
- Market Realist•2 months ago
Bluebird Bio Misses Analysts’ Estimates in Q2 2018
Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.
- Zacks•2 months ago
Medicines Company (MDCO) Q2 Loss Narrows, Revenues Tank Y/Y
The Medicines Company (MDCO) beats earnings estimates while missing the same for revenues in the second quarter.
